Tags

Type your tag names separated by a space and hit enter

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Int Immunopharmacol. 2020 Jul 01; 86:106749.II

Abstract

In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world. Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells. Many studies have reported the clinical characteristics of COVID-19: sudden deterioration of disease around 1-2 weeks after onset; much lower level of lymphocytes, especially natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP). About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2. It has been demonstrated clinical benefits for the patients with rheumatoid arthritis (RA), active systemic lupus erythematosus and atopic dermatitis with good efficacy and safety records. Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19. Several clinical trials are currently investigating the drug, and one of which has been completed with encouraging results. In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clinical trials progress and drug instruction from the US FDA, so as to provide reference for the treatment of severe COVID-19.

Authors+Show Affiliations

Department of Pharmacy, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.Research Department, Wuxi Maternal and Child Health Hospital Attached to Nanjing Medical University, Wuxi 214002, Jiangsu, China.Center of Clinical Research, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.Lung Transplant Center, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.Department of Pharmacy, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China. Electronic address: qizhigang058518@163.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32645632

Citation

Zhang, Xiuhong, et al. "Baricitinib, a Drug With Potential Effect to Prevent SARS-COV-2 From Entering Target Cells and Control Cytokine Storm Induced By COVID-19." International Immunopharmacology, vol. 86, 2020, p. 106749.
Zhang X, Zhang Y, Qiao W, et al. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020;86:106749.
Zhang, X., Zhang, Y., Qiao, W., Zhang, J., & Qi, Z. (2020). Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. International Immunopharmacology, 86, 106749. https://doi.org/10.1016/j.intimp.2020.106749
Zhang X, et al. Baricitinib, a Drug With Potential Effect to Prevent SARS-COV-2 From Entering Target Cells and Control Cytokine Storm Induced By COVID-19. Int Immunopharmacol. 2020 Jul 1;86:106749. PubMed PMID: 32645632.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. AU - Zhang,Xiuhong, AU - Zhang,Yan, AU - Qiao,Weizhen, AU - Zhang,Ji, AU - Qi,Zhigang, Y1 - 2020/07/01/ PY - 2020/05/05/received PY - 2020/06/06/revised PY - 2020/06/25/accepted PY - 2020/7/10/pubmed PY - 2020/7/10/medline PY - 2020/7/10/entrez KW - Baricitinib KW - COVID-19 KW - Cytokine storm KW - JAK-STAT KW - Pharmaceutical care SP - 106749 EP - 106749 JF - International immunopharmacology JO - Int. Immunopharmacol. VL - 86 N2 - In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world. Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells. Many studies have reported the clinical characteristics of COVID-19: sudden deterioration of disease around 1-2 weeks after onset; much lower level of lymphocytes, especially natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP). About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2. It has been demonstrated clinical benefits for the patients with rheumatoid arthritis (RA), active systemic lupus erythematosus and atopic dermatitis with good efficacy and safety records. Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19. Several clinical trials are currently investigating the drug, and one of which has been completed with encouraging results. In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clinical trials progress and drug instruction from the US FDA, so as to provide reference for the treatment of severe COVID-19. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/32645632/Baricitinib,_a_drug_with_potential_effect_to_prevent_SARS-COV-2_from_entering_target_cells_and_control_cytokine_storm_induced_by_COVID-19 L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(20)31418-1 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.